کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3345945 | 1215756 | 2013 | 7 صفحه PDF | دانلود رایگان |

Treatment of cells with interferon-γ leads to the replacement of the constitutive catalytic proteasome subunits β1, β2, and β5 by the inducible subunits LMP2 (β1i), MECL-1 (β2i), and LMP7 (β5i), respectively, building the so-called immunoproteasome. The incorporation of these subunits is required for the production of numerous MHC class-I restricted T cell epitopes. Recently, new evidence for an involvement of the immunoproteasome in other facets of the immune response emerged. Investigations of autoimmune diseases in animal models and a genetic predisposition of β5i in human autoimmune disorders suggest a crucial function of the immunoproteasome in proinflammatory diseases. The recent elucidation of the high-resolution structure of the immunoproteasome will facilitate the design of immunoproteasome selective inhibitors for pharmacological intervention.
Figure optionsDownload high-quality image (288 K)Download as PowerPoint slideHighlights
► Lessons from the high resolution structure of the immunoproteasome about its function.
► The antigen processing phenotype of mice devoid of all immunoproteasome subunits.
► The function of the immunoproteasome in directing T helper cell differentiation.
► The potential of LMP7 inhibitors for the treatment of autoimmune diseases.
► The symptoms of human diseases caused by mutations in the PSMB8 gene encoding LMP7.
Journal: Current Opinion in Immunology - Volume 25, Issue 1, February 2013, Pages 74–80